PYXIS ONCOLOGY INC (PYXS) Stock Price, Forecast & Analysis
NASDAQ:PYXS • US7473241013
PYXS Key Statistics, Chart & Performance
The current stock price of PYXS is 1.3 USD. In the past month the price decreased by -29.35%. In the past year, price decreased by -1.52%.
PYXS Technical Analysis
PYXS Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to PYXS. Both the profitability and financial health of PYXS have multiple concerns.
PYXS Financial Highlights
Over the last trailing twelve months PYXS reported a non-GAAP Earnings per Share(EPS) of -1.25. The EPS decreased by -21.36% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -78.14% | ||
| ROE | -109.86% | ||
| Debt/Equity | 0 |
PYXS Forecast & Estimates
15 analysts have analysed PYXS and the average price target is 6.55 USD. This implies a price increase of 404.12% is expected in the next year compared to the current price of 1.3.
For the next year, analysts expect an EPS growth of -42.67% and a revenue growth -79.64% for PYXS
PYXS Ownership
PYXS Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 15.94 | 409.148B | ||
| AMGN | AMGEN INC | 16.38 | 198.801B | ||
| GILD | GILEAD SCIENCES INC | 17.38 | 192.281B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 24.11 | 124.696B | ||
| REGN | REGENERON PHARMACEUTICALS | 17.29 | 84.911B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 46.93 | 41.535B | ||
| INSM | INSMED INC | N/A | 31.724B | ||
| BIIB | BIOGEN INC | 12.92 | 28.841B | ||
| NTRA | NATERA INC | N/A | 28.695B | ||
| UTHR | UNITED THERAPEUTICS CORP | 16.07 | 20.396B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About PYXS
Company Profile
Pyxis Oncology, Inc. engages in the business of developing a multi-modality portfolio of next-generation therapeutics to target difficult-to-treat cancers and improve quality of life for patients. The company is headquartered in Boston, Massachusetts and currently employs 44 full-time employees. The company went IPO on 2021-10-08. The firm is building therapeutics that hold the potential for mono and combination therapies. Its clinical program portfolio includes micvotobart pelidotin (MICVO), PYX-106, Sotigalimab (PYX-107), PYX-203, PYX-102, and APX601. The Company’s lead product candidate, MICVO, is an antibody-drug conjugate (ADC) that targets Extradomain-B Fibronectin (EDB+FN), a non-cellular structural component of the tumor extra-cellular matrix (ECM). MICVO is designed to generate a multi-pronged attack on difficult-to-treat cancers by directly killing cancer cells, reducing ECM density, inhibiting tumor angiogenesis and mobilizing an anti-tumor immune response. The Company’s ADC, MICVO, consists of human Immunoglobulin G1 (IgG1) and is site-specifically conjugated with a cleavable linker and a microtubule inhibitor (optimized auristatin) payload.
Company Info
PYXIS ONCOLOGY INC
321 Harrison Avenue
Boston MASSACHUSETTS US
Employees: 44
Phone: 16172219059
PYXIS ONCOLOGY INC / PYXS FAQ
What does PYXS do?
Pyxis Oncology, Inc. engages in the business of developing a multi-modality portfolio of next-generation therapeutics to target difficult-to-treat cancers and improve quality of life for patients. The company is headquartered in Boston, Massachusetts and currently employs 44 full-time employees. The company went IPO on 2021-10-08. The firm is building therapeutics that hold the potential for mono and combination therapies. Its clinical program portfolio includes micvotobart pelidotin (MICVO), PYX-106, Sotigalimab (PYX-107), PYX-203, PYX-102, and APX601. The Company’s lead product candidate, MICVO, is an antibody-drug conjugate (ADC) that targets Extradomain-B Fibronectin (EDB+FN), a non-cellular structural component of the tumor extra-cellular matrix (ECM). MICVO is designed to generate a multi-pronged attack on difficult-to-treat cancers by directly killing cancer cells, reducing ECM density, inhibiting tumor angiogenesis and mobilizing an anti-tumor immune response. The Company’s ADC, MICVO, consists of human Immunoglobulin G1 (IgG1) and is site-specifically conjugated with a cleavable linker and a microtubule inhibitor (optimized auristatin) payload.
Can you provide the latest stock price for PYXIS ONCOLOGY INC?
The current stock price of PYXS is 1.3 USD. The price decreased by -3.7% in the last trading session.
What is the dividend status of PYXIS ONCOLOGY INC?
PYXS does not pay a dividend.
What is the ChartMill technical and fundamental rating of PYXS stock?
PYXS has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
On which exchange is PYXS stock listed?
PYXS stock is listed on the Nasdaq exchange.
Is PYXIS ONCOLOGY INC (PYXS) expected to grow?
The Revenue of PYXIS ONCOLOGY INC (PYXS) is expected to decline by -79.64% in the next year. Check the estimates tab for more information on the EPS, Sales, EBIT and EBITDA future analyst estimates.
What is the Short Interest ratio of PYXIS ONCOLOGY INC (PYXS) stock?
The outstanding short interest for PYXIS ONCOLOGY INC (PYXS) is 4.95% of its float.